Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phoenixin-14 Downregulation as a Novel Prognostic Biomarker in Sepsis: Molecular and Clinical Evidence

NCT07356739 is registered in ClinicalTrials.gov with Firat University as lead sponsor.

NCT NCT07356739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07356739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phoenixin-14 Downregulation as a Novel Prognostic Biomarker in Sepsis: Molecular and Clinical Evidence
Lead sponsor
Firat University
Phase
Observational
Overall status
Completed
Start date
April 1, 2024
Completion date
June 30, 2025
Enrollment
77 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

phoenixin-14 molecular downregulation, sepsis - to reduce mortality in the intensive care unit, sepsis biomarker